Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Dan Legault
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focus |
pain and inflammation therapeutics
|
| gptkbp:founded |
2009
|
| gptkbp:founder |
gptkb:John_Wallace
|
| gptkbp:headquarters_location |
gptkb:Toronto
|
| https://www.w3.org/2000/01/rdf-schema#label |
Antibe Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
ATB-346
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
gastrointestinal safety of NSAIDs
|
| gptkbp:stockExchange |
gptkb:TSX_Venture_Exchange
|
| gptkbp:stockSymbol |
gptkb:ATE
|
| gptkbp:technology |
hydrogen sulfide-releasing drugs
|
| gptkbp:website |
https://antibethera.com/
|
| gptkbp:bfsParent |
gptkb:John_L._Wallace
|
| gptkbp:bfsLayer |
7
|